The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents.
暂无分享,去创建一个
S. Mangani | M. Costi | P. Linciano | C. Pozzi | M. Tonelli | D. Tondi | A. Cordeiro-da-Silva | R. Luciani | S. Ferrari | M. Santucci | Lorenzo Tagliazucchi | G. Tassone | G. Witt | C. Moraes | G. Landi | Sheraz Gul | N. Santarém | Laura Bertarini | Luca Costantino
[1] Kimberley M. Zorn,et al. High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents , 2023, Journal of medicinal chemistry.
[2] E. Chatelain,et al. State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation , 2023, Research and reports in tropical medicine.
[3] G. Santos-Gomes,et al. Parasitic Infection and Immunity—A Special Biomedicines Issue , 2022, Biomedicines.
[4] Maria Paola Costi,et al. Current Treatments to Control African Trypanosomiasis and One Health Perspective , 2022, Microorganisms.
[5] D. Horn. A profile of research on the parasitic trypanosomatids and the diseases they cause , 2022, PLoS neglected tropical diseases.
[6] Maria Paola Costi,et al. Repurposing the Trypanosomatidic GSK Kinetobox for the Inhibition of Parasitic Pteridine and Dihydrofolate Reductases , 2021, Pharmaceuticals.
[7] Maria Paola Costi,et al. Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase , 2021, Pharmaceuticals.
[8] Samuel Dean. Basic Biology of Trypanosoma brucei with reference to the development of chemotherapies. , 2021, Current pharmaceutical design.
[9] Bilge Debelec Butuner,et al. Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds. , 2020, Archiv der Pharmazie.
[10] Maria Paola Costi,et al. High-resolution crystal structure of Trypanosoma brucei pteridine reductase 1 in complex with an innovative tricyclic-based inhibitor. , 2020, Acta crystallographica. Section D, Structural biology.
[11] J. Estaquier,et al. Antileishmanial Drugs Modulate IL-12 Expression and Inflammasome Activation in Primary Human Cells , 2020, The Journal of Immunology.
[12] G. Murilla,et al. Differential virulence of Trypanosoma brucei rhodesiense isolates does not influence the outcome of treatment with anti-trypanosomal drugs in the mouse model , 2020, bioRxiv.
[13] Maria Paola Costi,et al. Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. , 2020, European journal of medicinal chemistry.
[14] E. Akl,et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. , 2019, The Lancet. Infectious diseases.
[15] V. Eifler-Lima,et al. Targeting pteridine reductase 1 and dihydrofolate reductase: the old is a new trend for leishmaniasis drug discovery. , 2019, Future medicinal chemistry.
[16] Maria Paola Costi,et al. Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors. , 2019, ACS infectious diseases.
[17] Magambo Phillip Kimuda,et al. Identification of Novel Potential Inhibitors of Pteridine Reductase 1 in Trypanosoma brucei via Computational Structure-Based Approaches and in Vitro Inhibition Assays , 2019, Molecules.
[18] M. Castilho,et al. Dual and selective inhibitors of pteridine reductase 1 (PTR1) and dihydrofolate reductase-thymidylate synthase (DHFR-TS) from Leishmania chagasi , 2019, Journal of enzyme inhibition and medicinal chemistry.
[19] A. Pinto,et al. Folates in Trypanosoma brucei: Achievements and Opportunities , 2018, ChemMedChem.
[20] R. López-Vélez,et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge , 2017, PLoS neglected tropical diseases.
[21] V. Avery,et al. Leishmaniasis drug discovery: recent progress and challenges in assay development. , 2017, Drug discovery today.
[22] C. Cárdenas,et al. Identification of a type I nitroreductase gene in non-virulent Trypanosoma rangeli , 2017, Memorias do Instituto Oswaldo Cruz.
[23] Maria Paola Costi,et al. Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity , 2017, Molecules.
[24] Shuguang Yuan,et al. Using PyMOL as a platform for computational drug design , 2017 .
[25] Maria Paola Costi,et al. Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. , 2016, Journal of medicinal chemistry.
[26] U. Rashid,et al. Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents. , 2016, European journal of medicinal chemistry.
[27] R. Wall,et al. The Epidemiology of Parasitic Diseases , 2015 .
[28] A. Khalaf,et al. Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1 , 2014, Journal of medicinal chemistry.
[29] P. Kennedy. Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness) , 2013, The Lancet Neurology.
[30] Michael P. Barrett,et al. Management of trypanosomiasis and leishmaniasis , 2012, British medical bulletin.
[31] P. Kaye,et al. Leishmaniasis: complexity at the host–pathogen interface , 2011, Nature Reviews Microbiology.
[32] S. McNicholas,et al. Presenting your structures: the CCP4mg molecular-graphics software , 2011, Acta crystallographica. Section D, Biological crystallography.
[33] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[34] C. Burri,et al. Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda , 2011, PLoS neglected tropical diseases.
[35] A. Fairlamb,et al. Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma brucei and Leishmania major* , 2011, The Journal of Biological Chemistry.
[36] W. Hunter,et al. Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases† , 2009, Journal of medicinal chemistry.
[37] A. Buschini,et al. Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole , 2009, Journal of parasitology research.
[38] S. Daulouède,et al. [Immunology and immunopathology of African trypanosomiasis]. , 2006, Medecine tropicale : revue du Corps de sante colonial.
[39] A. Fairlamb,et al. Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate , 2006, Molecular microbiology.
[40] Stephen M Beverley,et al. Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. , 2005, Journal of molecular biology.
[41] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[42] Gordon A. Leonard,et al. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites , 2001, Nature Structural Biology.
[43] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[44] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[45] Alexei Vagin,et al. Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.
[46] Karen N. Allen,et al. research papers Acta Crystallographica Section D Biological , 2003 .
[47] P. Evans. Biological Crystallography an Introduction to Data Reduction: Space-group Determination, Scaling and Intensity Statistics , 2022 .